The iCAD stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, Data-Driven rating system and does not include human intervention.
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. It operates through the Cancer Detection and Cancer Therapy business segments. The Cancer Detection segment includes image analysis and clinical decision support solutions for mammography, breast tomosynthesis, and computed tomography imaging. The Cancer Therapy segment offers an isotope-free cancer treatment platform technology. The company was founded in 1984 and is headquartered in Nashua, NH.
What was iCAD’s price range in the past 12 months?
iCAD lowest stock price was $8.32 and its highest was $21.44 in the past 12 months.
What is iCAD’s market cap?
iCAD’s market cap is $454.64M.
What is iCAD’s price target?
The average price target for iCAD is $24.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $28.00 ,the lowest forecast is $22.00. The average price target represents 32.89% Increase from the current price of $18.21.
What do analysts say about iCAD?
iCAD’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
When is iCAD’s upcoming earnings report date?
iCAD’s upcoming earnings report date is Aug 10, 2021 which is next month.
How were iCAD’s earnings last quarter?
iCAD released its earnings results on Apr 28, 2021. The company reported -$0.069 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.044.
Is iCAD overvalued?
According to Wall Street analysts iCAD’s price is currently Undervalued.
Does iCAD pay dividends?
iCAD does not currently pay dividends.
What is iCAD’s EPS estimate?
iCAD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iCAD have?
iCAD has 24,970,000 shares outstanding.
What happened to iCAD’s price movement after its last earnings report?
iCAD reported an EPS of -$0.069 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went down -1.205%.
Which hedge fund is a major shareholder of iCAD?
Among the largest hedge funds holding iCAD’s share is Driehaus Capital Management LLC. It holds iCAD’s shares valued at 3M.